Q-omics provides the consensus-scored PDZD9 profile across patient tissues and cancer cell-line models. PDZD9 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PDZD9 is differentially expressed in 13, with the highest sampling consensus in LUSC. Additionally, PDZD9 RNA expression shows 16,557 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LUSC, and UVM as cancer lineages where PDZD9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDZD9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDZD9 survival associations across molecular data types. PDZD9 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDZD9 RNA expression–survival associations across cancer types. High PDZD9 expression shows unfavorable associations in KIRC, ACC and LUSC, but favorable associations in UCS, LGG and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for PDZD9 RNA expression.
This table summarizes PDZD9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PDZD9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDZD9 shows lower tumor expression in LUSC, UCEC, BLCA, COAD, LUAD and BRCA. The LUSC box plot shows higher PDZD9 RNA expression in normal versus tumor tissue (log2 FC = −0.385, t-test p < 0.001).
This table shows molecular features associated with PDZD9 in patient tissues and cancer cell lines. In patient samples, PDZD9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDZD9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
